Research Paper Volume 14, Issue 15 pp 6255—6268

Targeting circRNA-MAP4K2 for the treatment of diabetes-induced retinal vascular dysfunction

class="figure-viewer-img"

Figure 3. cMAP4K2 regulates retinal vascular dysfunction in DR. (A and B) C57BL/6 mice received an intraocular injection of scramble (Scr) shRNA, cMAP4K2 shRNA, null vector, cMAP4K2 overexpressed vector, or left untreated (Ctrl) for 2 weeks. qRT-PCR assays were performed to detect the expression levels of cMAP4K2 and MAP4K2 mRNA (n = 5, *P < 0.05 vs. Ctrl group). (C and D) The mice were infused with Evans blue dye for 2 h. The fluorescence signal of flat-mounted retina was observed. A representative image and the quantification of Evans blue leakage was shown. Scale bar: 500 μm. (E) ELISA assays were performed to examine the amount of IL-2, IL-6, and TNF-α in retinal lysates among different groups (n = 5; *P < 0.05 vs. DR group; #P < 0.05 between the marked groups). The significant difference was analyzed by the Kruskal-Wallis test followed by the post hoc Bonferroni test.